Peter Doshi

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 9

Top Topics

Coronavirus Disease

Machine Learning

Drug Administration

Top Venues

BMJ evidence-based medicine

Journal of evaluation in clinical practice

Clinical trials (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Kaiser Fung, Mark Jones, Peter Doshi
Sources of bias in observational studies of covid-19 vaccine effectiveness. Journal of evaluation in clinical practice (2023)
Peter Doshi, Kaiser Fung
How the case counting window affected vaccine efficacy calculations in randomized trials of COVID-19 vaccines. Journal of evaluation in clinical practice (2023)
Isaac Bai, Peter Doshi, Matthew Herder
How to use the regulatory data from Health Canada for secondary analyses on new drugs, biologics and vaccines. BMJ evidence-based medicine (2023)
Kaiser Fung, Mark Jones, Peter Doshi
Sources of bias in observational studies of covid-19 vaccine effectiveness. Journal of evaluation in clinical practice (2023)
Kyungwan Hong, Anisa Rowhani-Farid, Peter Doshi
Definition and rationale for placebo composition: Cross-sectional analysis of randomized trials and protocols published in high-impact medical journals. Clinical trials (London, England) (2023)
Sarah Tanveer, Anisa Rowhani-Farid, Kyungwan Hong, Tom Jefferson, Peter Doshi
Transparency of COVID-19 vaccine trials: decisions without data. BMJ evidence-based medicine (2021)
Tom Jefferson, Maryanne Demasi, Peter Doshi
Statins for primary prevention: what is the regulator's role? BMJ evidence-based medicine (2020)
Peter Doshi, Florence Bourgeois, Kyungwan Hong, Mark Jones, Haeyoung Lee, Larissa Shamseer, O'Mareen Spence, Tom Jefferson
Adjuvant-containing control arms in pivotal quadrivalent human papillomavirus vaccine trials: restoration of previously unpublished methodology. BMJ evidence-based medicine 25 (6) (2020)
O'Mareen Spence, Kyungwan Hong, Richie Onwuchekwa Uba, Peter Doshi
Availability of study protocols for randomized trials published in high-impact medical journals: A cross-sectional analysis. Clinical trials (London, England) 17 (1) (2019)